✦ LIBER ✦

Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients

✍ Scribed by T. Guglielmelli; S. Bringhen; S. Rrodhe; F. Gay; F. Cavallo; A. Berruti; V. Montefusco; E. Piro; G. Benevolo; M.T. Petrucci; T. Caravita; M. Offidani; P. Corradini; M. Boccadoro; G. Saglio; A. Palumbo

Book ID: 116430656
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 138 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2010.12.026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

Impact of high-risk cytogenetics and pri

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

✍ Avet-Loiseau, H; Soulier, J; Fermand, J-P; Yakoub-Agha, I; Attal, M; Hulin, C; G 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 313 KB

Impact on response and survival of DNA r

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide

✍ María Teresa Cibeira; Carlos Fernández de Larrea; Alfons Navarro; Tania Díaz; Do 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 332 KB

Treatment of patients with relapsed/refr

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

✍ Dimopoulos, M A; Kastritis, E; Christoulas, D; Migkou, M; Gavriatopoulou, M; Gko 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 473 KB